Clock
Penumbra is not a dislocated compounder waiting to re-rate. It is a company under a definitive agreement to be acquired by Boston Scientific at $374 per share, signed January 14–15, 2026 and expected to close in the second half of 2026. The gap that closes is a merger-arbitrage spread — $321.19 to $374, about 16% gross — not a multi-year recovery. The name's own history of 52–63% drawdowns no longer governs; the deal, now in an FTC Second Request, does.
The clock is a merger, not a cycle
The event that re-recognizes value here is already named, priced, and dated. On January 14, 2026 Penumbra signed an Agreement and Plan of Merger under which Boston Scientific acquires the company, valuing each share at $374 and the enterprise at roughly $14.5 billion [1]. Holders elect, per share, either $374 in cash or 3.8721 Boston Scientific shares, with proration to roughly 73% cash and 27% stock [2], [3]. Chief executive Adam Elsesser has said he will take all stock and join Boston Scientific's board on close [4]. The transaction is subject to Penumbra stockholder approval and customary regulatory clearances, and the parties expect to complete it in 2026 [5].
The spread is the whole re-rating. At $321.19 (July 31, 2026) against $374 of deal consideration, the gross spread is $52.81, or 16.4% to deal value — and unlike a cycle repricing, its timing is governed by a regulatory calendar rather than by earnings. The market's reaction on announcement was the largest volume day in Penumbra's listed history: 9.67 million shares on January 15, 2026, roughly ten times its trailing pace, lifting the stock from $313.43 the prior close to $350.49. That volume spike is a deal-repricing event, the mirror image of the forced, fear-driven capitulation this framework hunts.
| Date | Event | Bearing on the clock |
|---|---|---|
| Jan 14, 2026 | Merger Agreement signed at $374/share, ~$14.5B EV | Fixes the payout; caps upside at deal value |
| Jan 15, 2026 | Deal announced; stock $313 → $350 on 9.7M shares | Re-rating already largely absorbed |
| Mar 16, 2026 | FTC issues Second Request (HSR waiting period extended) | Pushes close later, widens the spread |
| ~H2 / year-end 2026 | Expected close, pending clearances + stockholder vote | The re-recognition date, inside 18 months |
| Nov 4, 2026 | Q3 2026 earnings (no guidance issued pending deal) | Secondary; numbers subordinate to the deal |
Sources: merger terms and timing from the Q2 FY2026 10-Q merger note [6] and the January 15, 2026 announcement [7], [8]; price and volume from the run's daily price series; FTC Second Request (March 16, 2026) from Boston Scientific's Form S-4 / 424B3 registration statement and contemporaneous reporting.
The FTC Second Request, received March 16, 2026, is the live variable in the timing. It extends the HSR waiting period until both parties substantially comply, and it is why the close guidance moved to the second half of 2026. Reporting on the deal notes limited direct product overlap between the two companies, which bears on — but does not decide — the antitrust path; European Union and other non-U.S. competition and foreign-investment clearances also apply. Since the Second Request, the spread has widened rather than tightened: the stock drifted from $350 in late January to $321 by end-July, so the market now discounts the $374 outcome by more than it did on signing — a function of the lengthening timeline and of the 27% stock portion's exposure to Boston Scientific's own share price.
Base rates from Penumbra's own history
Penumbra has been a volatile compounder since its 2015 IPO, and its price has swung far more than its business. Its two deepest drawdowns are the relevant reference points — and both took two to two and a half years to complete a round trip.
Source: derived from the run's daily closing-price series, 2015-09-18 to 2026-07-31; an episode is a peak-to-trough close decline of 25% or more, measured to the first close back above the prior peak.
Source: derived from the run's daily closing-price series; round-trip is peak date to the first close reclaiming that peak.
Two features matter for the clock. First, the deep episodes are slow: the 2021 top ($311, April 2021) did not fully recover until May 2023, about 24 months; the 2023 top ($344, June 2023) troughed at $164 in August 2024 and did not reclaim its high until January 2026, roughly 31 months. A quality franchise that swings 50–63% and takes two-plus years to round-trip is exactly the kind of instrument the framework's 18-month horizon is built for — in the ordinary case. Second, and decisively here, that last round trip was completed by the takeover, not by operating recovery: the day before the deal the stock was $313.43, still 9% below its 2023 high; the merger pop carried it across. The most recent deep drawdown did not heal on its own.
The present decline is not one of these episodes. From the January 27, 2026 high of $359.40 — itself a deal-inflated level — the stock is down 10.6% to $321.19. That is not a fear-driven dislocation; it is the merger-arbitrage spread widening after the FTC Second Request. On operating fundamentals the company is still growing: Q2 2026 revenue was $390.0 million, up from $339.5 million a year earlier (+14.9%), and first-half revenue was $764.8 million against $663.6 million [9]. The current episode therefore has no precedent in Penumbra's history as a dislocation, because it is not one.
The 18-month test
Re-recognition here is expected within roughly six months, not eighteen: Boston Scientific and Penumbra guide to a 2026 close [10], and second-half completion is well inside the framework's window. But what gets "recognized" is capped: $374 in cash-or-stock, a defined outcome, not a multi-year compounding recovery. The path does not require cycle repair; it requires the deal to close — stockholder approval plus clearance of the FTC Second Request and the EU and other non-U.S. reviews. The read, stated once: this is a defined-payout merger on a regulatory clock, and the clock runs to a ceiling, not to a re-rating. What would falsify it is the deal failing to fire — the FTC or a foreign regulator blocking or forcing remedies that break economics, or stockholders rejecting the vote — which would return the stock toward its undisturbed pre-announcement level near $313 (January 14, 2026), and plausibly lower given the negative signal; its trailing-12-month low was $224.84. That deal-break case is the entry in the falsifier ledger this tab owns.
What consensus expects
The sell side is not capitulated — it is anchored to the takeout. Analyst price targets cluster at the deal: a mean of $361.58 and a median and high of $374, against a low of $320 that sits essentially at the current price (consensus of 13 analysts; source: run estimates feed). The spread of targets is the spread of the deal: $374 if it closes, roughly today's price if the market simply holds it pending the vote. That is the opposite of the capitulated, target-slashed positioning the framework looks for — no one is pricing distress; the tape is pricing a takeout with a discount for time and regulatory risk.
Consensus does not need a printed quarter to recognize value here; it needs a closing. Penumbra issued no forward guidance on its Q2 2026 report specifically because of the pending transaction, and the next print — Q3 2026, around November 4, 2026 — is subordinate to the deal calendar. The candidate quarter for "recognition" is not an earnings date at all; it is the close.
Instrument facts
Penumbra is an optionable NYSE large-cap ($12.6 billion market capitalization), so listed options, including longer-dated series, exist on the name. Two facts qualify that. First, the pending cash-and-stock merger has collapsed volatility: 30-day realized volatility was about 5.7% on July 31, 2026, near the lowest reading in the name's history (its historical band runs from roughly 5% to 91%, with a median near 37%) — the signature of a stock pinned to a fixed deal price rather than trading on its fundamentals. Second, a current implied-volatility level, and the detail of any long-dated option chain, were not verifiable from available public sources — the options-data pages checked returned access-denied responses. Consistent with this guide's discipline: long-dated option-implied-volatility data was not verifiable from available sources, and no IV figure is estimated here.
Source: 30-day realized volatility and its historical band from the run's technical-analysis feed (volatility series, as of 2026-07-31); market capitalization from the run's market-cap derivation.
The framework's own consequence follows as a fact, not advice. A name whose price is governed by a $374 takeout expected to close within the year is a defined-outcome situation with volatility already extinguished — a merger spread, not the fear-driven dislocation in an essential compounder that this system underwrites over an 18-month-plus horizon. On that basis the framework routes Penumbra to the watchlist rather than the book. The related evidence sits in the drawdown anatomy (Dislocation), the damage arithmetic (Damage Math), and the framework-fit summary (Fit).